{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:35:22Z","timestamp":1792427722941,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s00296-015-3379-x","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T07:26:11Z","timestamp":1444029971000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study"],"prefix":"10.1007","volume":"36","author":[{"given":"Tadashi","family":"Okano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Inui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sugioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Wakitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"3379_CR1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME (2001) Rheumatoid arthritis. Lancet 358:903\u2013911","journal-title":"Lancet"},{"key":"3379_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780380202","volume":"38","author":"WP Arend","year":"1995","unstructured":"Arend WP, Dayer JM (1995) Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 38:151\u2013160","journal-title":"Arthritis Rheum"},{"key":"3379_CR3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1146\/annurev.med.51.1.207","volume":"51","author":"RN Maini","year":"2000","unstructured":"Maini RN, Taylor PC (2000) Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 51:207\u2013229","journal-title":"Annu Rev Med"},{"key":"3379_CR4","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"3379_CR5","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/art.10308","volume":"46","author":"MC Genovese","year":"2002","unstructured":"Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46:1443\u20131450","journal-title":"Arthritis Rheum"},{"key":"3379_CR6","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50:1400\u20131411","journal-title":"Arthritis Rheum"},{"key":"3379_CR7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374:210\u2013221","journal-title":"Lancet"},{"key":"3379_CR8","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1093\/rheumatology\/kes150","volume":"51","author":"ME Weinblatt","year":"2012","unstructured":"Weinblatt ME, Fleischmann R, Huizinga TW et al (2012) Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. Rheumatology 51:2204\u20132214","journal-title":"Rheumatology"},{"key":"3379_CR9","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:2817\u20132829","journal-title":"Arthritis Rheum"},{"key":"3379_CR10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R, Paulus H, Strand V (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727\u2013735","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"3379_CR11","doi-asserted-by":"crossref","first-page":"i21","DOI":"10.1136\/ard.59.suppl_1.i21","volume":"59","author":"N Nishimoto","year":"2000","unstructured":"Nishimoto N, Kishimoto T, Yoshizaki K (2000) Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis 59(Suppl 1):i21\u201327","journal-title":"Ann Rheum Dis"},{"key":"3379_CR12","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1002\/art.10623","volume":"46","author":"EH Choy","year":"2002","unstructured":"Choy EH, Isenberg DA, Garrood T et al (2002) Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 46:3143\u20133150","journal-title":"Arthritis Rheum"},{"key":"3379_CR13","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","volume":"67","author":"P Emery","year":"2008","unstructured":"Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:1516\u20131523","journal-title":"Ann Rheum Dis"},{"key":"3379_CR14","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ (2008) Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 58:2968\u20132980","journal-title":"Arthritis Rheum"},{"key":"3379_CR15","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","volume":"50","author":"N Nishimoto","year":"2004","unstructured":"Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50:1761\u20131769","journal-title":"Arthritis Rheum"},{"key":"3379_CR16","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, Investigators O (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371:987\u2013997","journal-title":"Lancet"},{"key":"3379_CR17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","volume":"54","author":"H Forsblad-d\u2019Elia","year":"2015","unstructured":"Forsblad-d\u2019Elia H, Bengtsson K, Kristensen LE, Jacobsson LT (2015) Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology 54:1186\u20131193","journal-title":"Rheumatology"},{"key":"3379_CR18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","volume":"53","author":"YM Pers","year":"2014","unstructured":"Pers YM, Fortunet C, Constant E et al (2014) Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 53:76\u201384","journal-title":"Rheumatology"},{"key":"3379_CR19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FPC.0000000000000071","volume":"24","author":"C Enevold","year":"2014","unstructured":"Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, Jacobsen S, Nielsen CH (2014) Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics 24:401\u2013405","journal-title":"Pharmacogenet Genomics"},{"key":"3379_CR20","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/rheumatology\/keu363","volume":"54","author":"CI Da\u00efen","year":"2015","unstructured":"Da\u00efen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J (2015) High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. Rheumatology 54:601\u2013608","journal-title":"Rheumatology"},{"key":"3379_CR21","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acr.20537","volume":"63","author":"K Kume","year":"2011","unstructured":"Kume K, Amano K, Yamada S, Hatta K, Kuwaba N, Ohta H (2011) Very early improvements in the wrist and hand assessed by power Doppler sonography predicting later favorable responses in tocilizumab-treated patients with rheumatoid arthritis. Arthritis Care Res 63:1477\u20131481","journal-title":"Arthritis Care Res"},{"key":"3379_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00001721-199010000-00013","volume":"1","author":"DL Amrani","year":"1990","unstructured":"Amrani DL (1990) Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. Blood Coagul Fibrinolysis 1:443\u2013446","journal-title":"Blood Coagul Fibrinolysis"},{"key":"3379_CR23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00928938","volume":"142","author":"P Conti","year":"1995","unstructured":"Conti P, Bartle L, Barbacane RC, Reale M, Sipe JD (1995) The down-regulation of IL-6-stimulated fibrinogen steady state mRNA and protein levels by human recombinant IL-1 is not PGE2-dependent: effects of IL-1 receptor antagonist (IL-1RA). Mol Cell Biochem 142:171\u2013178","journal-title":"Mol Cell Biochem"},{"key":"3379_CR24","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/ajcp\/102.6.802","volume":"102","author":"KM Rao","year":"1994","unstructured":"Rao KM, Pieper CS, Currie MS, Cohen HJ (1994) Variability of plasma IL-6 and crosslinked fibrin dimers over time in community dwelling elderly subjects. Am J Clin Pathol 102:802\u2013805","journal-title":"Am J Clin Pathol"},{"key":"3379_CR25","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/jgs.13133","volume":"62","author":"SG Wannamethee","year":"2014","unstructured":"Wannamethee SG, Whincup PH, Lennon L, Papacosta O, Lowe GD (2014) Associations between fibrin D-dimer, markers of inflammation, incident self-reported mobility limitation, and all-cause mortality in older men. J Am Geriatr Soc 62:2357\u20132362","journal-title":"J Am Geriatr Soc"},{"key":"3379_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315\u2013324","journal-title":"Arthritis Rheum"},{"key":"3379_CR27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van\u2019t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44\u201348","journal-title":"Arthritis Rheum"},{"key":"3379_CR28","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","volume":"7","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, Smolen JS (2005) Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7:R796\u2013806","journal-title":"Arthritis Res Ther"},{"key":"3379_CR29","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM Gestel van","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845\u20131850","journal-title":"Arthritis Rheum"},{"key":"3379_CR30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","volume":"23","author":"JF Fries","year":"1980","unstructured":"Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137\u2013145","journal-title":"Arthritis Rheum"},{"key":"3379_CR31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-540-73259-4_7","volume":"181","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Kishimoto T (2008) Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 181:151\u2013160","journal-title":"Handb Exp Pharmacol"},{"key":"3379_CR32","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/PPA.S41433","volume":"7","author":"I Al-Shakarchi","year":"2013","unstructured":"Al-Shakarchi I, Gullick NJ, Scott DL (2013) Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 7:653\u2013666","journal-title":"Patient Prefer Adherence"},{"key":"3379_CR33","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1538-7836.2005.01365.x","volume":"3","author":"MW Mosesson","year":"2005","unstructured":"Mosesson MW (2005) Fibrinogen and fibrin structure and functions. J Thromb Haemost 3:1894\u20131904","journal-title":"J Thromb Haemost"},{"key":"3379_CR34","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1546-0096-9-8","volume":"9","author":"BE Gilliam","year":"2011","unstructured":"Gilliam BE, Reed MR, Chauhan AK, Dehlendorf AB, Moore TL (2011) Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J 9:8","journal-title":"Pediatr Rheumatol Online J"},{"key":"3379_CR35","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/03009739809178943","volume":"103","author":"NG Arvidsson","year":"1998","unstructured":"Arvidsson NG, Gudbj\u00f6rnsson B, H\u00e4llgren R, Larsson A (1998) Concordant message of different inflammatory markers in patients with rheumatoid arthritis. Ups J Med Sci 103:35\u201342","journal-title":"Ups J Med Sci"},{"key":"3379_CR36","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-06-165845","volume":"113","author":"SS Adam","year":"2009","unstructured":"Adam SS, Key NS, Greenberg CS (2009) D-dimer antigen: current concepts and future prospects. Blood 113:2878\u20132887","journal-title":"Blood"},{"key":"3379_CR37","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.ta.0000251420.41427.d3","volume":"63","author":"T Iba","year":"2007","unstructured":"Iba T, Gando S, Murata A et al (2007) Predicting the severity of systemic inflammatory response syndrome (SIRS)-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 63:1093\u20131098","journal-title":"J Trauma"},{"key":"3379_CR38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00540-005-0368-3","volume":"20","author":"Y Mukubo","year":"2006","unstructured":"Mukubo Y, Kawamata M (2006) Higher preoperative D-dimer value remain high postoperatively in patients with rheumatoid arthritis compared with those with osteoarthrosis. J Anesth 20:51\u201353","journal-title":"J Anesth"},{"key":"3379_CR39","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/eji.201141550","volume":"41","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) A clinical perspective of IL-1\u03b2 as the gatekeeper of inflammation. Eur J Immunol 41:1203\u20131217","journal-title":"Eur J Immunol"},{"key":"3379_CR40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.1998.tb08310.x","volume":"856","author":"W Kozak","year":"1998","unstructured":"Kozak W, Kluger MJ, Soszynski D, Conn CA, Rudolph K, Leon LR, Zheng H (1998) IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Ann N Y Acad Sci 856:33\u201347","journal-title":"Ann N Y Acad Sci"},{"key":"3379_CR41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.1998.tb08311.x","volume":"856","author":"M Zetterstr\u00f6m","year":"1998","unstructured":"Zetterstr\u00f6m M, Sundgren-Andersson AK, Ostlund P, Bartfai T (1998) Delineation of the proinflammatory cytokine cascade in fever induction. Ann N Y Acad Sci 856:48\u201352","journal-title":"Ann N Y Acad Sci"},{"key":"3379_CR42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1084\/jem.183.1.311","volume":"183","author":"Z Chai","year":"1996","unstructured":"Chai Z, Gatti S, Toniatti C, Poli V, Bartfai T (1996) Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice. J Exp Med 183:311\u2013316","journal-title":"J Exp Med"},{"key":"3379_CR43","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1152\/japplphysiol.01005.2001","volume":"92","author":"LR Leon","year":"2002","unstructured":"Leon LR (2002) Invited review: cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol 92:2648\u20132655","journal-title":"J Appl Physiol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3379-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-015-3379-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-015-3379-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,22]],"date-time":"2022-05-22T17:17:27Z","timestamp":1653239847000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-015-3379-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s00296-015-3379-x","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}